These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17016495

  • 1. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
    Freeman S, Bartlett JB, Convey G, Hardern I, Teague JL, Loxham SJ, Allen JM, Poucher SM, Charles AD.
    Br J Pharmacol; 2006 Nov; 149(6):775-85. PubMed ID: 17016495
    [Abstract] [Full Text] [Related]

  • 2. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 3. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
    Andersen B, Westergaard N.
    Biochem J; 2002 Oct 15; 367(Pt 2):443-50. PubMed ID: 12099891
    [Abstract] [Full Text] [Related]

  • 4. Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors.
    Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ.
    Am J Physiol Endocrinol Metab; 2005 Sep 15; 289(3):E366-72. PubMed ID: 15797986
    [Abstract] [Full Text] [Related]

  • 5. Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle.
    Baker DJ, Timmons JA, Greenhaff PL.
    Diabetes; 2005 Aug 15; 54(8):2453-9. PubMed ID: 16046314
    [Abstract] [Full Text] [Related]

  • 6. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
    Kaiser A, Nishi K, Gorin FA, Walsh DA, Bradbury EM, Schnier JB.
    Arch Biochem Biophys; 2001 Feb 15; 386(2):179-87. PubMed ID: 11368340
    [Abstract] [Full Text] [Related]

  • 7. Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes.
    Latsis T, Andersen B, Agius L.
    Biochem J; 2002 Nov 15; 368(Pt 1):309-16. PubMed ID: 12186629
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
    Gregus Z, Németi B.
    Toxicol Sci; 2007 Nov 15; 100(1):44-53. PubMed ID: 17693424
    [Abstract] [Full Text] [Related]

  • 10. Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors.
    Agius L.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1175-87. PubMed ID: 20716056
    [Abstract] [Full Text] [Related]

  • 11. Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.
    Docsa T, Czifrák K, Hüse C, Somsák L, Gergely P.
    Mol Med Rep; 2011 Oct 15; 4(3):477-81. PubMed ID: 21468595
    [Abstract] [Full Text] [Related]

  • 12. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL.
    Bioorg Med Chem Lett; 2005 Jan 17; 15(2):459-65. PubMed ID: 15603973
    [Abstract] [Full Text] [Related]

  • 13. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E, Gregory L, Teague J, Myatt J, Hammond C, Poucher SM, Jones HB.
    Toxicol Pathol; 2010 Apr 17; 38(3):393-401. PubMed ID: 20215584
    [Abstract] [Full Text] [Related]

  • 14. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site.
    Hampson LJ, Arden C, Agius L, Ganotidis M, Kosmopoulou MN, Tiraidis C, Elemes Y, Sakarellos C, Leonidas DD, Oikonomakos NG.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7835-45. PubMed ID: 16908161
    [Abstract] [Full Text] [Related]

  • 15. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149.
    Lerín C, Montell E, Nolasco T, García-Rocha M, Guinovart JJ, Gómez-Foix AM.
    Biochem J; 2004 Mar 15; 378(Pt 3):1073-7. PubMed ID: 14651477
    [Abstract] [Full Text] [Related]

  • 16. Effects in skeletal muscle.
    Young A.
    Adv Pharmacol; 2005 Mar 15; 52():209-28. PubMed ID: 16492548
    [Abstract] [Full Text] [Related]

  • 17. Integrated effects of multiple modulators on human liver glycogen phosphorylase a.
    Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ.
    Am J Physiol Endocrinol Metab; 2002 Jul 15; 283(1):E29-37. PubMed ID: 12067839
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modulation of glycogen phosphorylase activity affects 5-phosphoribosyl-1-pyrophosphate availability in rat hepatocyte cultures.
    Boer P, Sperling O.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct 15; 23(8-9):1235-9. PubMed ID: 15571236
    [Abstract] [Full Text] [Related]

  • 20. An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.
    Poucher SM, Freeman S, Loxham SJ, Convey G, Bartlett JB, De Schoolmeester J, Teague J, Walker M, Turnbull AV, Charles AD, Carey F, Berg S.
    Br J Pharmacol; 2007 Dec 15; 152(8):1239-47. PubMed ID: 17934512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.